The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors
Official Title: Peritumoral Injection of Immature Dendritic Cels to Irradiated Metastases of Solid Tumors
Study ID: NCT00278018
Brief Summary: Melanoma is the main cause of death in patients with skin cancer. Once it has metastasized, this cancer has been shown to respond to chemotherapy only in rare cases. Immunotherapy represents an approach to treatment based on the immune response to cancer antigens. The long-term objective of this study is to develop a therapeutic approach for the treatment of cancer in general, and melanoma in particular, based on immunotherapy, using a combination of local tumor irradiation followed by injection of immature dendritic cells (iDC).The treatment will be followed by the injection of interferon alpha, which we expect will induce activation of the iDC. This trial is based on the hypothesis that local radiation, which causes destruction of the tumor, in combination with injection of the patient's own iDC and the activation of these cells with interferon alpha, will induce an effective immune response against the tumor. In order to test the suggested approach, we propose a 20-patients clinical trial that will evaluate the objective clinical and immunological response to the proposed treatment in patients with malignant melanoma and other solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, , Israel
Name: Michal Lotem, MD
Affiliation: Hadassah Medical Organization, pob 12000, Jerusalem, Israel
Role: PRINCIPAL_INVESTIGATOR